Q2 2024 Earnings Summary
- NSP continues to maintain strong pricing power even in a challenging economic environment, leading to improved margins and profitability. Management stated they are having "very effective pricing efforts on both sides, new and renewing" and are maintaining their position as "the premium service offering in the marketplace." ( )
- The implementation of the Workday partnership is on track and is expected to become a significant growth driver in 2025, with management expressing excitement about its potential to accelerate growth. The company is "on track for early next year as planned" and believes the Workday relationship "absolutely can be" a material driver of sequential growth in early 2025. ( , )
- Healthcare benefit costs are normalizing, resulting in lower-than-expected expenses and contributing positively to margins and the EPS outlook. Pharmacy trend costs have come down from about 17% last year to "less than 10%" this year, and management sees the benefit cost trends "continuing over the remainder of the year" and "trending favorably." ( , )
- Decline in paid worksite employees: The average number of paid worksite employees decreased by 1% over the same period last year, primarily due to large account attrition and a challenging economic environment affecting small businesses. The company lowered its full-year outlook for average paid worksite employees to a range of 307,400 to 310,600, representing a decline of 0.5% to 1.5% compared to 2023. This lower starting point impacts growth projections for the second half of the year.
- Earnings boosted by one-time reserve adjustments: The strong gross profit per worksite employee was partially due to a favorable reserve adjustment stemming from overestimated incurred but not reported (IBNR) claims related to a healthcare breach. This adjustment contributed to earnings in the recent quarter but may not recur in future periods.
- Delayed growth acceleration due to lower starting point: The lower starting point for paid worksite employees is expected to delay significant sequential growth by a quarter, shifting anticipated growth reestablishment from the third to the fourth quarter. This indicates a delay in growth momentum and may affect overall annual performance.
-
Workday Partnership Progress
Q: Update on Workday partnership impact and expectations?
A: The Workday partnership is progressing well, with both companies preparing to offer a joint solution that could significantly impact the market in 2025. Insperity has invested about $19 million so far this year, on track for around $60 million in 2024. While contributions are expected in 2025, there is potential for impact on early 2025 growth due to larger account sizes and ongoing efforts to integrate offerings. -
Guidance and Conservatism
Q: Is guidance less conservative due to health care trends or cost actions?
A: The guidance reflects a combination of stronger pricing and favorable health care cost trends. Medical cost trends are at the low end of the 4.5% to 6% range, possibly even slightly lower. Insperity remains conservative in its estimates, but the favorable trends have allowed EBITDA and EPS outlooks to be maintained despite a lower worksite employee outlook. -
Pricing Trends and Strategy
Q: What's driving improved pricing despite client hesitation?
A: Pricing is strong due to effective efforts on new and renewing business. Insperity maintains its premium service offering, justifying higher prices through superior breadth, depth, and level of care. On renewing business, pricing is definitely up as per the strategic plan; on new business, it is about the same or slightly higher compared to last year. -
Health Care Cost Trends
Q: Update on health care benefit trends, especially pharmacy costs?
A: Pharmacy trends have normalized compared to last year's elevated levels. Last year's pharmacy trend was about 17%, driven by specialty drugs like Ozempic; this year, it's less than 10%. The trend has come down due to year-over-year comparisons, and this normalization is reflected in current modeling. -
Gross Margin Drivers
Q: Were there any adjustments benefiting gross margin per worksite employee?
A: Yes, a reserve adjustment on the medical side positively impacted Q2 earnings. Insperity had made a conservative estimate on IBNR due to a health care breach affecting payment processes. Claims paid in Q2 were lower than initially estimated, allowing for an appropriate reduction in reserves. -
Worksite Employee Outlook
Q: Can you break out the lower second-half outlook between client hiring and new business?
A: The biggest impact on unit growth outlook is the starting point being lower due to decreased client hiring. Uncertainty remains high, affecting net client hiring, especially through the election period. While sales execution is effective, lower-than-targeted paid worksite employees and less hiring as the quarter evolved have contributed to the reduced outlook. -
Competition and Market Environment
Q: Has the competitive environment become more aggressive?
A: The competitive environment is no more aggressive than it has been over the past year. Insperity continues to win its share of accounts, focusing on those that fit best. The overall activity level has affected volume more than competition, with some clients hesitating on final decisions or deferring start dates. -
Guidance Increase Breakdown
Q: Can you quantify the moving pieces in the guidance increase?
A: The guidance increase reflects a net effect of several factors. Lower worksite employee count is a drag but is offset by a $6 million beat in the quarter. The annual guidance is only going up $2 million, with a negative $4 million due to volume, offset by lower benefit trends and strong pricing. Expense management also contributed to maintaining guidance despite lower volumes.
Research analysts covering INSPERITY.